Taysha Gene Therapies : to Participate in Upcoming September Investor Healthcare Conferences
September 01, 2021 at 04:02 pm EDT
Share
Citi’s 16th Annual BioPharma Conference on September 8, 2021
Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021 at 5:00 pm ET
2021 Wells Fargo Virtual Healthcare Conference on September 10, 2021 at 1:20 pm ET
HC Wainwright 23rd Annual Global Investment Conference on September 13, 2021 at 7:00 am ET
SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines on September 23, 2021
2021 Cantor Virtual Global Healthcare Conference on September 27, 2021 at 8:00 am ET
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in the following investor healthcare conferences: Citi’s 16th Annual BioPharma Conference, Morgan Stanley 19th Annual Global Healthcare Conference, 2021 Wells Fargo Virtual Healthcare Conference, HC Wainwright 23rd Annual Global Investment Conference and the 2021 Cantor Virtual Global Healthcare Conference and the SVB Leerink CybeRx Series.
Conferences Details:
Event:
Citi’s 16th Annual BioPharma Conference
Date:
Wednesday September 8, 2021
Format:
1x1 meetings
Participants:
RA Session II, President, Founder and CEO
Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
Kamran Alam, Chief Financial Officer
Kimberly Lee, SVP, Corporate Communications and Investor Relations
Event:
Morgan Stanley 19th Annual Global Healthcare Conference
Date:
Thursday September 9, 2021
Time:
5:00 pm ET
Format:
Fireside chat
Participants:
RA Session II, President, Founder and CEO
Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
Kamran Alam, Chief Financial Officer
Event:
2021 Wells Fargo Virtual Healthcare Conference
Date:
Friday September 10, 2021
Time:
1:20 pm ET
Format:
Fireside chat
Participants:
RA Session II, President, Founder and CEO
Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
Kamran Alam, Chief Financial Officer
Event:
HC Wainwright 23rd Annual Global Investment Conference
Date:
Monday September 13, 2021
Time:
7:00 am ET
Format:
Fireside chat
Participants:
RA Session II, President, Founder and CEO
Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
Kamran Alam, Chief Financial Officer
Event:
SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicine
Date:
Thursday September 23, 2021
Format:
1x1 meetings
Participants:
RA Session II, President, Founder and CEO
Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
Kamran Alam, Chief Financial Officer
Kimberly Lee, SVP, Corporate Communications and Investor Relations
Event:
2021 Cantor Virtual Global Healthcare Conference
Date:
Monday September 27, 2021
Time:
8:00 am ET
Format:
Fireside Chat
Participants:
RA Session II, President, Founder and CEO
Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
Kamran Alam, Chief Financial Officer
Webcasts for these conferences will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005994/en/
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Companyâs lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). It received orphan drug designation from the European Commission for TSHA-120 for the treatment of GAN.
TAYSHA GENE THERAPIES, INC. 
